Bromide

Bromide

SCHEMBL23706016

CC(C)(C)OC(=O)NCc1cc2c[n+](Cc3ccccc3)ccc2cn1.[Br-]

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ACHE known ✓ P22303 1/20 0.37
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA7 P43166 1/20 0.42
CA14 Q9ULX7 1/20 0.42
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
KDM4A O75164 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
ATM Q13315 1/20 0.39
NTSR1 P30989 1/20 0.39
GLS O94925 1/20 0.38
NAMPT P43490 1/20 0.38
HDAC1 Q13547 1/20 0.38
BRD4 O60885 1/20 0.37
BCHE P06276 1/20 0.37
CKS1B P61024 1/20 0.37
SKP1 P63208 1/20 0.37
SKP2 Q13309 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3633138 0.81 KDM4A (0.54) CA12CA1KDM4AL3MBTL1NAMPT
Bromide SCHEMBL23063780 0.80 CA12 (0.50) CA12CA1CA7CA14MEN1
SCHEMBL30097039 0.73 NAMPT (0.45) CA12CA1KDM4AL3MBTL1NAMPT
SCHEMBL26143921 0.73 NAMPT (0.45) CA12CA1KDM4AL3MBTL1NAMPT
SCHEMBL31401432 0.72 GAA (0.42) MEN1KMT2AKDM4AL3MBTL1BRD4
SCHEMBL26143885 0.72 KDM4A (0.42) CA12CA1KDM4AL3MBTL1HDAC1
SCHEMBL30097062 0.72 KDM4A (0.42) CA12CA1KDM4AL3MBTL1HDAC1
SCHEMBL3838871 0.71 CA12 (0.63) CA12CA1CA7CA14MEN1
SCHEMBL23705856 0.71 GLS (0.47) CA12CA1CA7CA14MEN1
SCHEMBL23706123 0.70 ACACB (0.47) KDM4AHDAC1CKS1BSKP1SKP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12441726-B2 Compounds and uses thereof FOGHORN THERAPEUTICS, INC. (US) 2025-10-14 US disclosed
US-20230145003-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-11 US disclosed
EP-4096667-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 EP disclosed
WO-2021155320-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12441726-B2 Compounds and uses thereof VHL, CLN6, TFEB ACHE 4721/4885CA12 4343/4885CA1 4780/4885
US-20230145003-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB ACHE 4721/4885CA12 4343/4885CA1 4780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.